DE602005021534D1 - Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung - Google Patents
Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendungInfo
- Publication number
- DE602005021534D1 DE602005021534D1 DE602005021534T DE602005021534T DE602005021534D1 DE 602005021534 D1 DE602005021534 D1 DE 602005021534D1 DE 602005021534 T DE602005021534 T DE 602005021534T DE 602005021534 T DE602005021534 T DE 602005021534T DE 602005021534 D1 DE602005021534 D1 DE 602005021534D1
- Authority
- DE
- Germany
- Prior art keywords
- peptides
- amphipathic
- multidomade
- helixful
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61939204P | 2004-10-15 | 2004-10-15 | |
PCT/US2005/036933 WO2006044596A2 (en) | 2004-10-15 | 2005-10-14 | Multi-domain amphipathic helical peptides and methods of their use |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005021534D1 true DE602005021534D1 (de) | 2010-07-08 |
Family
ID=36203530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005021534T Active DE602005021534D1 (de) | 2004-10-15 | 2005-10-14 | Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung |
Country Status (9)
Country | Link |
---|---|
US (4) | US7572771B1 (de) |
EP (2) | EP2218736A1 (de) |
JP (1) | JP5091679B2 (de) |
AT (1) | ATE469174T1 (de) |
AU (1) | AU2005295640B2 (de) |
CA (1) | CA2584048C (de) |
DE (1) | DE602005021534D1 (de) |
ES (1) | ES2346771T3 (de) |
WO (1) | WO2006044596A2 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080227686A1 (en) * | 2006-06-16 | 2008-09-18 | Lipid Sciences, Inc. | Novel Peptides that Promote Lipid Efflux |
US20080138284A1 (en) * | 2006-09-26 | 2008-06-12 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
US20110059549A1 (en) | 2007-05-09 | 2011-03-10 | Coleman Matthew A | Methods and systems for producing nanolipoprotein particles |
US8936787B2 (en) | 2008-04-15 | 2015-01-20 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Peptides promoting lipid efflux |
WO2010020822A1 (en) * | 2008-08-19 | 2010-02-25 | University Of Patras | Therapy for apolipoprotein-induced hypertriglyceridemia |
US10151037B2 (en) | 2009-01-12 | 2018-12-11 | Lawrence Livermore National Security, Llc | Electrochemical flow-cell for hydrogen production and nicotinamide dependent target reduction, and related methods and systems |
WO2011066511A1 (en) | 2009-11-30 | 2011-06-03 | The U.S.A., As Represented By The Secretary Department Of Health And Human Services | Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof |
EA034702B1 (ru) * | 2011-04-26 | 2020-03-10 | Молекулар Экспресс, Инк. | Липосомные композиции |
EP2701725A1 (de) | 2011-04-29 | 2014-03-05 | Kinemed, Inc. | Chemische modifizierung von mimetischen apolipoproteinpeptiden zur herstellung von therapeutika |
US9644038B2 (en) | 2011-12-21 | 2017-05-09 | The Regents Of The University Of California | Apolipoprotein nanodiscs with telodendrimer |
AU2013299641A1 (en) | 2012-08-10 | 2015-03-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids |
CN104755618A (zh) | 2012-08-16 | 2015-07-01 | 合成基因组股份有限公司 | 数字生物转化器 |
WO2015057583A1 (en) | 2013-10-14 | 2015-04-23 | The United States Of America, As Represented By The Secretary | Treatment of chronic kidney disease with sahps |
CN106488987A (zh) | 2014-05-02 | 2017-03-08 | 塞勒尼斯医疗控股公司 | Hdl疗法标志物 |
US20160074473A1 (en) | 2014-07-31 | 2016-03-17 | Kinemed, Inc. | Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties |
US11529390B2 (en) * | 2015-03-19 | 2022-12-20 | Institut De Cardiologie De Montreal | PCSK9 inhibitory polypolypeptides and methods of use |
WO2017044899A1 (en) * | 2015-09-11 | 2017-03-16 | Lawrence Livermore National Security, Llc | Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation |
EP3490579A1 (de) | 2016-07-27 | 2019-06-05 | Hartis-Pharma SA | Therapeutische kombinationen zur behandlung von erythrozytendysfunktionen |
US11207422B2 (en) | 2017-05-02 | 2021-12-28 | Lawrence Livermore National Security, Llc | MOMP telonanoparticles, and related compositions, methods and systems |
US20200102356A1 (en) * | 2018-10-01 | 2020-04-02 | NMC Inc. | Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4643988A (en) | 1984-05-15 | 1987-02-17 | Research Corporation | Amphipathic peptides |
DE3436928A1 (de) * | 1984-10-09 | 1986-04-10 | Siegel, Rolf, Dr., 8700 Würzburg | Alloplastische gefaessprothese, verfahren zu deren herstellung |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
DE69321118T2 (de) | 1992-06-12 | 1999-06-02 | Naamloze Vennootschap Innogenetics S.A., Gent | Peptide und Proteine, Verfahren zur Ihren Herstellung und die Verwendung als Cholesterol-Annehmer |
AU6059898A (en) * | 1996-09-05 | 1998-03-26 | Uab Research Foundation, The | Anti-atherosclerotic peptides and a transgenic mouse model of atherosclerosis |
US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US7205280B2 (en) | 1998-03-11 | 2007-04-17 | Cognosci, Inc. | Methods of suppressing microglial activation |
US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
JP2003529375A (ja) | 2000-03-31 | 2003-10-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ヒト動脈壁細胞内で酸化脂質により誘発される遺伝子の制御 |
US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US6469007B2 (en) | 2000-11-28 | 2002-10-22 | Wyeth | Serotonergic agents |
US6930085B2 (en) * | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
EP2382983B1 (de) | 2004-09-02 | 2014-02-12 | Cognosci, Inc. | Verbesserte ApoE-Analoga und Verwendungsverfahren dafür |
GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
JP2010537638A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法 |
US8710429B2 (en) | 2007-12-21 | 2014-04-29 | The Board Of Regents Of The University Of Ok | Identification of biomarkers in biological samples and methods of using same |
-
2005
- 2005-10-14 EP EP10004512A patent/EP2218736A1/de not_active Withdrawn
- 2005-10-14 ES ES05815961T patent/ES2346771T3/es active Active
- 2005-10-14 CA CA2584048A patent/CA2584048C/en active Active
- 2005-10-14 DE DE602005021534T patent/DE602005021534D1/de active Active
- 2005-10-14 AU AU2005295640A patent/AU2005295640B2/en active Active
- 2005-10-14 JP JP2007536912A patent/JP5091679B2/ja active Active
- 2005-10-14 US US11/577,259 patent/US7572771B1/en active Active
- 2005-10-14 WO PCT/US2005/036933 patent/WO2006044596A2/en active Application Filing
- 2005-10-14 AT AT05815961T patent/ATE469174T1/de not_active IP Right Cessation
- 2005-10-14 EP EP05815961A patent/EP1812474B1/de active Active
-
2009
- 2009-07-02 US US12/497,443 patent/US8071746B2/en active Active
-
2010
- 2010-04-23 US US12/766,761 patent/US8148323B2/en active Active
-
2012
- 2012-02-28 US US13/407,132 patent/US8835378B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US8071746B2 (en) | 2011-12-06 |
US7572771B1 (en) | 2009-08-11 |
CA2584048A1 (en) | 2006-04-27 |
WO2006044596A8 (en) | 2006-06-29 |
US20090270331A1 (en) | 2009-10-29 |
AU2005295640B2 (en) | 2011-07-28 |
EP1812474B1 (de) | 2010-05-26 |
CA2584048C (en) | 2016-08-09 |
US20100203099A1 (en) | 2010-08-12 |
JP5091679B2 (ja) | 2012-12-05 |
ATE469174T1 (de) | 2010-06-15 |
JP2008516605A (ja) | 2008-05-22 |
AU2005295640A1 (en) | 2006-04-27 |
ES2346771T3 (es) | 2010-10-20 |
WO2006044596A3 (en) | 2006-09-08 |
EP1812474A2 (de) | 2007-08-01 |
WO2006044596A2 (en) | 2006-04-27 |
EP2218736A1 (de) | 2010-08-18 |
AU2005295640A2 (en) | 2006-04-27 |
US8148323B2 (en) | 2012-04-03 |
US8835378B2 (en) | 2014-09-16 |
US20120148642A1 (en) | 2012-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005021534D1 (de) | Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung | |
CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
ATE517638T1 (de) | Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln | |
ATE498395T1 (de) | Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung | |
DE602004022424D1 (de) | Proteasominhibitoren und verfahren zu deren anwendung | |
DE602005005810D1 (de) | Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen | |
WO2003089457A3 (en) | Peptide inhibitors of protein kinase c ϝ for pain management | |
ATE459621T1 (de) | Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung | |
DK1766077T3 (da) | Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse | |
ATE404188T1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten | |
DE602006012513D1 (de) | Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin | |
DE602005026398D1 (de) | System zur abgabe von flüchtigen stoffen | |
BR0315689A (pt) | Alvo para terapia de dano cognitivo | |
NO20051345L (no) | Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer | |
DE602005026866D1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
EA200801942A1 (ru) | Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон | |
ATE496892T1 (de) | Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen | |
ATE398921T1 (de) | Modulare anordnung und verfahren zum züchten von wassertieren | |
DE50010875D1 (de) | Verfahren zum einspritzen von kraftstoff und einspritzventil zur durchführung des verfahrens | |
DE602004017283D1 (de) | Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür | |
ATE519504T1 (de) | Chromatin-remodellierende substanzen zur erhöhung der expression von pdx-1 und förderung der zelldifferenzierung | |
TR199902192T2 (xx) | Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri | |
DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
BR0313588A (pt) | Métodos para o tratamento da demência com base em apo e genótipo | |
DE602006016413D1 (de) | Kim-1-antikörper zur behandlung von th2-vermittelten erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |